All > Denver > Colorado

Phase 1/1B Monotherapy for Colorectal Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Colorectal Cancer+3 MoreMRTX0902 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This is a Phase 1/2, open-label, multicenter, study evaluating the safety, tolerability, PK, PD, and anti-tumor activity of MRTX0902 alone and in combination with MRTX849 (adagrasib) in patients with advanced solid tumor malignancy harboring mutations in the KRAS, MAPK pathways.

Eligible Conditions
  • Non-Small Cell Lung Cancer
  • Solid Tumors
  • Advanced Solid Tumors
  • Colorectal Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Expansion Phase
1
ZN-A-1041 100mg
1
RMC-6236

Study Objectives

6 Primary · 6 Secondary · Reporting Duration: 2 years

2 years
Phase 2: Duration of response (DOR)
Phase 2: Objective response rate (ORR)
Phase 2: Overall survival (OS)
Phase 2: Progression free survival (PFS)
21 Days
Phase 1: Number of Patients who Experience Dose-Limiting Toxicity
Up to 2 years
Phase1/1B: Number of patients who experience a treatment-related adverse event
Up to 4 days
Apparent total plasma clearance when dosed orally
Apparent volume of distribution when dosed orally
Area under the plasma concentration versus time curve
Maximum observed plasma concentration
Terminal elimination half-life
Time to achieve maximal plasma concentration

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
Expansion Phase
1
ZN-A-1041 100mg
1
RMC-6236

Trial Design

3 Treatment Groups

Phase 1/1B Monotherapy
1 of 3
Phase 1/1B Combination Therapy
1 of 3
Phase 2
1 of 3

Experimental Treatment

225 Total Participants · 3 Treatment Groups

Primary Treatment: Phase 1/1B Monotherapy · No Placebo Group · Phase 1 & 2

Phase 1/1B Monotherapy
Drug
Experimental Group · 1 Intervention: MRTX0902 · Intervention Types: Drug
Phase 1/1B Combination TherapyExperimental Group · 2 Interventions: MRTX0902, MRTX849 · Intervention Types: Drug, Drug
Phase 2Experimental Group · 2 Interventions: MRTX0902, MRTX849 · Intervention Types: Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MRTX849
2021
Completed Phase 1
~10

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years

Who is running the clinical trial?

Mirati Therapeutics Inc.Lead Sponsor
59 Previous Clinical Trials
6,977 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 9 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Patients with KRAS G12C mutation are eligible for this study.
Treatment is not available or patient refuses treatment.
You have evaluable disease.
You have measurable disease.\n
You have a tumor lesion amenable to mandatory biopsy at baseline and on-study.
You have no known organ dysfunction.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top